[Pulmonary lymphangiomyomatosis: a 3-year follow-up of medroxyprogesterone acetate therapy. Apropos of a case].
A 41-year-old female patient presenting with chylothorax was found to have pulmonary lymphangiomyomatosis. Recurrence led to parietal pleurectomy. Lung biopsy performed at surgery confirmed the histology diagnosis. Hormone treatment with medroxyprogesterone acetate was initiated immediately and administered via intramuscular injections each month. The treatment was continued for three years and regular clinical, functional and radiologic follow-up provided evidence of response: radiologic and functional stability were achieved at the cost of major secondary effects of hormone therapy. This rare, apparently hormone-dependent, disease raises the problem of the long-term benefit of treatment.
Druelle
S
S
Service de Pneumologie et Unité de Réanimation Respiratoire, CHU, Amiens.
Aubry
P
P
Levi-Valensi
P
P
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008171:Lung Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018192:Lymphangioleiomyomatosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D005082:Physical Exertion; D012129:Respiratory Function Tests
D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate
La lymphangiomyomatose pulmonaire: suivi à trois ans sous acétate de médroxyprogestérone. A propos d'un cas.